A Harvard University neuroscientist with more than 20 years of experience in drug discovery and new technology development will speak on “Drug Discovery Strategies for Neurodegenerative Diseases” from noon to 1 p.m. Thursday (Dec. 18) at the Riley Outpatient Center Auditorium, 575 Riley Hospital Drive, in Indianapolis.
Dr. Marcie Glicksman, co-director of Laboratory for Drug Discovery in Neurodegeneration at the Harvard NeuroDiscovery Center, is the latest presenter in the Indiana Clinical and Translational Sciences Institute’s Translational Medicine Distinguished Speaker Series. Her expertise includes assay development, high-throughput screening and chemical databases, animal pharmacology and preclinical development. She previously served at Descartes Therapeutics, a company that develops pain therapeutics using imaging techniques, and Cubist, focused on anti-infectives. She also served at DuPont-Merck (later DuPont Pharmaceuticals) and Cephalon. She has led multiple advanced programs for neurodegenerative diseases, including co-inventorship of a drug candidate that has been in Phase III clinical trials.
Glicksman served on the Board of Directors for the Society for Biomolecular Sciences (now Society for Laboratory Automation and Screening) from 2005 to 2009. She is part of the science advisory board for the Alzheimer’s Disease Foundation and the California Institute for Regenerative Medicine. She also reviews grants for the National Institutes of Health, the Michael J. Fox Foundation for Parkinson’s Research, Alzheimer’s Association and International Rett Syndrome Foundation. Glicksman co-founded the Academic Drug Discovery Consortium and regularly consults on filing investigational new drug applications with the U.S. Food and Drug Administration, as well as projects that involve new technology development.